TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies

In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including: Current clinical use of Dato-DXd in previously treated EGFR-mutated NSCLC, including evidence from TROPION-Lung01 and TROPION-Lung05 and considerations for treatment sequencing Emerging efficacy data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and the potential role of these agents in earlier lines of therapy Ongoing clinical trials evaluating TROP2 ADCs alone and in combination with immunotherapy, chemotherapy, or EGFR-targeted therapies, including TROPION-Lung07, TROPION-Lung08, TROPION-Lung14, TROPION-Lung15, and AVANZAR Biomarker-guided patient selection, including the potential of the TROP2 QCS-NMR biomarker to identify patients most likely to benefit from Dato-DXd Safety and supportive care considerations, including prevention and management of stomatitis, ocular toxicities, and interstitial lung disease/pneumonitis Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Christine M. Bestvina, MD Associate Professor of Medicine Section of Hematology/Oncology Division of Medicine University of Chicago Medicine Chicago, Illinois Joshua E. Reuss, MD Thoracic Medical Oncologist Director of Thoracic Clinical Research Associate Professor of Medicine Georgetown Lombardi Comprehensive Cancer Center Washington, DC Link to full program: https://bit.ly/4iumiap Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.